Collabody is ITRI’s proprietary protein drug discovery platform which utilizes a short triplex-forming collagen-like peptide to make multivalent protein binders. Due to the avidity effect of the trivalent nature of the molecule, Collabody can greatly enhance target binding strength and crosslinking potency in comparison to the bivalent monoclonal antibody IgG counterpart. The characteristics and benefits of Collabody are as follows. 1. Recombinantly making multi-trivalent protein binders in mammalian cells by fusion of target-binding partners with a short collagen-like peptide scaffold. 2. The triplex structure of Collabody is thermally stable. 3. The collagen-like scaffold is derived from human serum collagens and has been proven to be non-immunogenic. 4. The scaffold is capable of self-nucleation and propagation of the heterologous fusion partners from either the N- or C- terminal, or both directions. Therefore, Collabody is very flexible in drug design to create trivalent and bispecific products with enhanced avidity and functionality.